BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37965265)

  • 1. Engineering a dual vaccine against COVID-19 and tuberculosis.
    Guthrie CM; Tan X; Meeker AC; Self AE; Liu L; Cheng Y
    Front Cell Infect Microbiol; 2023; 13():1273019. PubMed ID: 37965265
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Jia Q; Masleša-Galić S; Nava S; Horwitz MA
    mBio; 2022 Jun; 13(3):e0068722. PubMed ID: 35642945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of a Mycobacterium ulcerans Ag85B-EsxH Fusion Protein in Recombinant BCG Improves Experimental Buruli Ulcer Vaccine Efficacy.
    Hart BE; Lee S
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005229. PubMed ID: 27941982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of protective efficacy conferred by a recombinant Mycobacterium bovis BCG expressing a fusion protein of Ag85A-ESAT-6.
    Deng YH; He HY; Zhang BS
    J Microbiol Immunol Infect; 2014 Feb; 47(1):48-56. PubMed ID: 23357605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Immunogenicity and Protective Efficacy Elicited by Mycobacterium bovis BCG Overexpressing Ag85A Protein against Mycobacterium tuberculosis Aerosol Infection.
    Xu ZZ; Chen X; Hu T; Meng C; Wang XB; Rao Y; Zhang XM; Yin YL; Pan ZM; Jiao XA
    Front Cell Infect Microbiol; 2016; 6():3. PubMed ID: 26858942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in mice.
    Sali M; Di Sante G; Cascioferro A; Zumbo A; Nicolò C; Donà V; Rocca S; Procoli A; Morandi M; Ria F; Palù G; Fadda G; Manganelli R; Delogu G
    Infect Immun; 2010 Dec; 78(12):5202-13. PubMed ID: 20921146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection.
    Yuan X; Teng X; Jing Y; Ma J; Tian M; Yu Q; Zhou L; Wang R; Wang W; Li L; Fan X
    Appl Microbiol Biotechnol; 2015 Dec; 99(24):10587-95. PubMed ID: 26363555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and protective efficacy conferred by a novel recombinant Mycobacterium bovis bacillus Calmette-Guérin strain expressing interleukin-12p70 of human cytokine and Ag85A of Mycobacterium tuberculosis fusion protein.
    Deng YH; He HY; Zhang FJ
    Scand J Immunol; 2013 Dec; 78(6):497-506. PubMed ID: 24283772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of BCG prime-DNA booster and rBCG regimens for protection against tuberculosis.
    Tan K; Liang J; Teng X; Wang X; Zhang J; Yuan X; Fan X
    Hum Vaccin Immunother; 2014; 10(2):391-8. PubMed ID: 24192709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manipulation of BCG vaccine: a double-edged sword.
    Singh VK; Srivastava R; Srivastava BS
    Eur J Clin Microbiol Infect Dis; 2016 Apr; 35(4):535-43. PubMed ID: 26810060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A recombinant selective drug-resistant M. bovis BCG enhances the bactericidal activity of a second-line anti-tuberculosis regimen.
    Chiwala G; Liu Z; Mugweru JN; Wang B; Khan SA; Bate PNN; Yusuf B; Hameed HMA; Fang C; Tan Y; Guan P; Hu J; Tan S; Liu J; Zhong N; Zhang T
    Biomed Pharmacother; 2021 Oct; 142():112047. PubMed ID: 34426260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis.
    Tchilian EZ; Desel C; Forbes EK; Bandermann S; Sander CR; Hill AV; McShane H; Kaufmann SH
    Infect Immun; 2009 Feb; 77(2):622-31. PubMed ID: 19064635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant Bacillus Calmette-Guérin Expressing SARS-CoV-2 Chimeric Protein Protects K18-hACE2 Mice against Viral Challenge.
    Mambelli F; Marinho FV; Andrade JM; de Araujo ACVSC; Abuna RPF; Fabri VMR; Santos BPO; da Silva JS; de Magalhães MTQ; Homan EJ; Leite LCC; Dias GBM; Heck N; Mendes DAGB; Mansur DS; Báfica A; Oliveira SC
    J Immunol; 2023 Jun; 210(12):1925-1937. PubMed ID: 37098890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis.
    Sun R; Skeiky YA; Izzo A; Dheenadhayalan V; Imam Z; Penn E; Stagliano K; Haddock S; Mueller S; Fulkerson J; Scanga C; Grover A; Derrick SC; Morris S; Hone DM; Horwitz MA; Kaufmann SH; Sadoff JC
    Vaccine; 2009 Jul; 27(33):4412-23. PubMed ID: 19500523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Genome Region of Difference 4 (RD4) on Mycobacterial Virulence and BCG Efficacy.
    Ru H; Liu X; Lin C; Yang J; Chen F; Sun R; Zhang L; Liu J
    Front Cell Infect Microbiol; 2017; 7():239. PubMed ID: 28642843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
    Romano M; D'Souza S; Adnet PY; Laali R; Jurion F; Palfliet K; Huygen K
    Vaccine; 2006 Apr; 24(16):3353-64. PubMed ID: 16488518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular immune responses to recombinant Mycobacterium bovis BCG constructs expressing major antigens of region of difference 1 of Mycobacterium tuberculosis.
    Shaban K; Amoudy HA; Mustafa AS
    Clin Vaccine Immunol; 2013 Aug; 20(8):1230-7. PubMed ID: 23761657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superinfection with SARS-CoV-2 Has Deleterious Effects on Mycobacterium bovis BCG Immunity and Promotes Dissemination of Mycobacterium tuberculosis.
    Hildebrand RE; Chandrasekar SS; Riel M; Touray BJB; Aschenbroich SA; Talaat AM
    Microbiol Spectr; 2022 Oct; 10(5):e0307522. PubMed ID: 36200898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New disease old vaccine: Is recombinant BCG vaccine an answer for COVID-19?
    Gupta PK
    Cell Immunol; 2020 Oct; 356():104187. PubMed ID: 32745670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.